Oticon Alta

Auris Medicals AM-111 Obtains FDA Orphan Drug Designation for the Treatment of Acute Sensorineural Hearing Loss

Auris Medicals otoprotective drug AM-111 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of acute sensorineural hearing loss (ASNHL), a condition which may occur following various inner ear injuries. ASNHL may be provoked by exposure to excessive noise, viral or bacterial infections in the inner ear, disturbances of the inner ear blood supply, middle and inner ear surgery and a variety of other incidents. If left untreated, ASNHL may result in permanent, irreversible hearing loss. The clinical development with AM-111 was launched in January 2006 with a phase I/II clinical trial evaluating the drugs safety in patients with ASNHL from acute acoustic trauma.

The FDAs orphan drug program is designed to promote the development of treatments for diseases that affect fewer than 200,000 patients in the USA. It provides certain incentives such as waiver of FDA user fees, tax credits, funding support for clinical trials, study design assistance, or market exclusivity for up to seven years following marketing approval. The orphan drug program is administered by the Office of Orphan Products Development.

More information can be found at www.aurismedical.com/

Share this Article

Comment

Related Content
Preferred Professionals Near You
See More Preferred Professionals

Clinics above not close enough?
Search with your zipcode below.

Sign Up for Our eNewsletter
Our free eNewsletter is delivered to your inbox every two weeks - it’s the best way to stay informed about what’s new at Healthy Hearing!
Preferred Hearing Professionals Near You

Jeffrey H. Aroesty MD, PC

400 Valley Rd Ste 105
Mount Arlington, NJ 07856

Click Here for Details

Total Hearing Care - Hillsborough

311 Courtyard Dr
Hillsborough, NJ 08844

Click Here for Details

ENT and Allergy Associates, LLP - Bridgewater

245 US HWY 22 W 3rd fl
Bridgewater, NJ 08807

Click Here for Details